CanSino Biologics (6185) Announces EGM Results, Amended Articles, and Board Adjustments

Bulletin Express11-27

CanSino Biologics Inc. (the “Company,” stock code: 6185) convened its 2025 second extraordinary general meeting (EGM) on November 27, 2025. Attendance included 132,670,900 H shares, with 35.82% in person or by proxy, and 114,372,901 A shares (excluding 406,098 repurchased shares) with 38.53% in person or by proxy. All resolutions proposed were approved by poll, including special and ordinary resolutions; two director appointments were passed via cumulative voting.

Effective November 27, 2025, the Company’s Articles of Association have been amended. The EGM also confirmed the election of two independent non-executive directors, Mr. Man Cho (左敏) and Ms. Xuefeng Ji (紀雪峰), whose terms will extend until the expiration of the third session of the Board of Directors.

Following the EGM, the Board approved adjustments to its committees, effective immediately until the current Board session ends. The Audit Committee is chaired by Mr. Yiu Leung Andy Cheung and comprises Ms. Ji and Mr. Li. The Remuneration and Assessment Committee is chaired by Mr. Cho, with Mr. Cheung, Ms. Ji, Mr. Li, and Dr. Yu serving as members. The Nomination Committee is chaired by Ms. Ji, supported by Mr. Cho and Dr. Yu.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102986252?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102986252","market":"us","top_or_hot":-1,"title":"CanSino Biologics (6185) Announces EGM Results, Amended Articles, and Board Adjustments","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (the “Company,” stock code: 6185) convened its 2025 second extraordinary general meeting (EGM) on November 27, 2025. Attendance included 132,670,900 H shares, with 35.82% in person or by proxy, and 114,372,901 A shares (excluding 406,098 repurchased shares) with 38.53% in person or by proxy. All resolutions proposed were approved by poll, including special and ordinary resolutions; two director appointments were passed via cumulative voting.</p>\n<p>Effective November 27, 2025, the Company’s Articles of Association have been amended. The EGM also confirmed the election of two independent non-executive directors, Mr. Man Cho (左敏) and Ms. Xuefeng Ji (紀雪峰), whose terms will extend until the expiration of the third session of the Board of Directors.</p>\n<p>Following the EGM, the Board approved adjustments to its committees, effective immediately until the current Board session ends. The Audit Committee is chaired by Mr. Yiu Leung Andy Cheung and comprises Ms. Ji and Mr. Li. The Remuneration and Assessment Committee is chaired by Mr. Cho, with Mr. Cheung, Ms. Ji, Mr. Li, and Dr. Yu serving as members. The Nomination Committee is chaired by Ms. Ji, supported by Mr. Cho and Dr. Yu.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics (6185) Announces EGM Results, Amended Articles, and Board Adjustments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics (6185) Announces EGM Results, Amended Articles, and Board Adjustments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-27 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (the “Company,” stock code: 6185) convened its 2025 second extraordinary general meeting (EGM) on November 27, 2025. Attendance included 132,670,900 H shares, with 35.82% in person or by proxy, and 114,372,901 A shares (excluding 406,098 repurchased shares) with 38.53% in person or by proxy. All resolutions proposed were approved by poll, including special and ordinary resolutions; two director appointments were passed via cumulative voting.</p>\n<p>Effective November 27, 2025, the Company’s Articles of Association have been amended. The EGM also confirmed the election of two independent non-executive directors, Mr. Man Cho (左敏) and Ms. Xuefeng Ji (紀雪峰), whose terms will extend until the expiration of the third session of the Board of Directors.</p>\n<p>Following the EGM, the Board approved adjustments to its committees, effective immediately until the current Board session ends. The Audit Committee is chaired by Mr. Yiu Leung Andy Cheung and comprises Ms. Ji and Mr. Li. The Remuneration and Assessment Committee is chaired by Mr. Cho, with Mr. Cheung, Ms. Ji, Mr. Li, and Dr. Yu serving as members. The Nomination Committee is chaired by Ms. Ji, supported by Mr. Cho and Dr. Yu.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1102986252","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102986252","pubTimestamp":1764248590,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (the “Company,” stock code: 6185) convened its 2025 second extraordinary general meeting (EGM) on November 27, 2025. Attendance included 132,670,900 H shares, with 35.82% in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物(6185)公布临时股东大会结果、修订章程及董事会调整","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (the “Company,” stock code: 6185) convened its 2025 second extraordinary general meeting (EGM) on November 27, 2025. Attendance included 132,670,900 H shares, with 35.82% in person or by proxy, and 114,372,901 A shares (excluding 406,098 repurchased shares) with 38.53% in person or by proxy. All resolutions proposed were approved by poll, including special and ordinary resolutions; two director appointments were passed via cumulative voting.\nEffective November 27, 2025, the Company’s Articles of Association have been amended. The EGM also confirmed the election of two independent non-executive directors, Mr. Man Cho (左敏) and Ms. Xuefeng Ji (紀雪峰), whose terms will extend until the expiration of the third session of the Board of Directors.\nFollowing the EGM, the Board approved adjustments to its committees, effective immediately until the current Board session ends. The Audit Committee is chaired by Mr. Yiu Leung Andy Cheung and comprises Ms. Ji and Mr. Li. The Remuneration and Assessment Committee is chaired by Mr. Cho, with Mr. Cheung, Ms. Ji, Mr. Li, and Dr. Yu serving as members. The Nomination Committee is chaired by Ms. Ji, supported by Mr. Cho and Dr. Yu.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102986252","isCrawlerRequest":true}